« Back
01/19/10



Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117

Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117

Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117

Rockville, MD, January 19, 2010 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.

“In addition to our co-development partnership with Teva, this European patent award further validates the commercial potential of RX-3117,” said Dr. Chang Ahn, Rexahn’s Chairman and Chief Executive Officer. “The development of RX-3117 strengthens our oncology pipeline, which includes ArchexinTM, currently in Phase II clinical trials.”

RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis. Potential indications of RX-3117 are solid tumors including colon, lung and pancreatic cancers. In preclinical trials, RX-3117 has demonstrated its ability to overcome cancer drug resistance in cancer cells, in particular, gemcitabine-resistance in the human lung cancer cell. The US patent issued for RX-3117 claims composition of matter, synthesis, and methods (2008).

In September 2009, Rexahn announced a commercialization and development agreement with Teva for RX-3117. Under the agreement, Rexahn will be eligible to receive additional development, regulatory and sales milestone payments and royalties on net sales worldwide.

Contact

The Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com



©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy